1. Home
  2. ATYR vs BRDG Comparison

ATYR vs BRDG Comparison

Compare ATYR & BRDG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATYR
  • BRDG
  • Stock Information
  • Founded
  • ATYR 2005
  • BRDG 2009
  • Country
  • ATYR United States
  • BRDG United States
  • Employees
  • ATYR N/A
  • BRDG N/A
  • Industry
  • ATYR Biotechnology: Biological Products (No Diagnostic Substances)
  • BRDG Investment Managers
  • Sector
  • ATYR Health Care
  • BRDG Finance
  • Exchange
  • ATYR Nasdaq
  • BRDG Nasdaq
  • Market Cap
  • ATYR 330.7M
  • BRDG 323.7M
  • IPO Year
  • ATYR 2015
  • BRDG 2021
  • Fundamental
  • Price
  • ATYR $3.87
  • BRDG $9.60
  • Analyst Decision
  • ATYR Strong Buy
  • BRDG Hold
  • Analyst Count
  • ATYR 6
  • BRDG 6
  • Target Price
  • ATYR $18.60
  • BRDG $10.67
  • AVG Volume (30 Days)
  • ATYR 2.1M
  • BRDG 682.6K
  • Earning Date
  • ATYR 03-13-2025
  • BRDG 05-07-2025
  • Dividend Yield
  • ATYR N/A
  • BRDG 4.78%
  • EPS Growth
  • ATYR N/A
  • BRDG N/A
  • EPS
  • ATYR N/A
  • BRDG 0.13
  • Revenue
  • ATYR $235,000.00
  • BRDG $419,220,000.00
  • Revenue This Year
  • ATYR $1,387.23
  • BRDG N/A
  • Revenue Next Year
  • ATYR $873.22
  • BRDG $26.25
  • P/E Ratio
  • ATYR N/A
  • BRDG $74.33
  • Revenue Growth
  • ATYR N/A
  • BRDG 61.35
  • 52 Week Low
  • ATYR $1.42
  • BRDG $6.21
  • 52 Week High
  • ATYR $4.66
  • BRDG $11.69
  • Technical
  • Relative Strength Index (RSI)
  • ATYR 54.43
  • BRDG 55.92
  • Support Level
  • ATYR $2.98
  • BRDG $9.14
  • Resistance Level
  • ATYR $4.32
  • BRDG $9.79
  • Average True Range (ATR)
  • ATYR 0.41
  • BRDG 0.37
  • MACD
  • ATYR 0.06
  • BRDG -0.06
  • Stochastic Oscillator
  • ATYR 72.14
  • BRDG 43.75

About ATYR aTyr Pharma Inc. Common Stock

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

About BRDG Bridge Investment Group Holdings Inc.

Bridge Investment Group Holdings Inc is a vertically integrated investment manager, diversified across specialized asset classes. The company combines its nationwide operating platform with dedicated teams of investment professionals focused on various specialized and synergistic investment platforms, including real estate, credit, renewable energy, and secondaries strategies. Its broad range of products and vertically integrated structure allow it to capture new market opportunities and serve investors with various investment objectives. The company operates Its business in a single segment, alternative investment management, diversified across specialized and synergistic investment platforms.

Share on Social Networks: